Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
8.49
-0.14 (-1.62%)
Jul 30, 2026, 1:34 PM CST
SHA:603520 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 2,471 | 2,446 | 2,350 | 2,196 | 2,131 | 2,000 |
Revenue Growth | 3.23% | 4.06% | 7.02% | 3.04% | 6.57% | 46.29% |
Gross Profit Gross Profit Growth | 508.73 | 472.85 | 430.39 | 507.69 | 502.59 | 744.81 |
Operating Income Operating Income Growth | 104.39 | 83.4 | 62.77 | 151.57 | 139.14 | 441.12 |
Net Income Net Income Growth | 16.84 | 10.23 | -49.1 | 44.23 | -75.85 | 323.75 |
Earnings Per Share EPS Growth | 0.03 | 0.02 | -0.12 | 0.13 | -0.22 | 0.94 |
EPS Growth | - | - | - | - | - | 31.60% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
CMO/CDMO CMO/CDMO Growth | 40.54 |
Contrast Agent Contrast Agent Growth | 2,135 |
Others Others Growth | 22.97 |
Quinolone Quinolone Growth | 36.25 |
Total Total Growth | 2,234 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 308.01 | 415.34 | 603.35 | 565.16 | 662.44 | 845.9 |
Total Debt Total Debt Growth | 3,043 | 2,966 | 2,659 | 3,056 | 2,782 | 1,908 |
Net Cash (Debt) Net Cash Growth | -2,735 | -2,550 | -2,056 | -2,491 | -2,120 | -1,062 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -5.51 | -4.99 | -5.02 | -7.32 | -6.15 | -3.08 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -153.53 | 3.67 | 193.5 | 44.55 | -78.37 | 508.84 |
Capital Expenditures CapEx Growth | -245.75 | -269.2 | -480.62 | -266.22 | -472.18 | -303.88 |
Free Cash Flow Free Cash Flow Growth | -399.28 | -265.53 | -287.12 | -221.67 | -550.56 | 204.96 |
Free Cash Flow Growth | - | - | - | - | - | 861.68% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 20.59% | 19.33% | 18.31% | 23.12% | 23.58% | 37.24% |
Operating Margin | 4.22% | 3.41% | 2.67% | 6.90% | 6.53% | 22.06% |
Pretax Margin | 0.74% | 0.29% | -2.43% | 2.07% | -3.07% | 19.77% |
Profit Margin | 0.68% | 0.42% | -2.09% | 2.01% | -3.56% | 16.19% |
FCF Margin | -16.16% | -10.86% | -12.22% | -10.09% | -25.83% | 10.25% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.300 | 0.300 | 0.150 | - | 0.500 | 0.357 |
Dividend Per Share Growth | 100.00% | 100.00% | - | - | 40.02% | 0% |
Dividend Yield | 3.55% | 3.27% | 1.80% | - | 2.71% | 0.82% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 254.56 | 402.90 | - | 109.03 | - | 49.07 |
Forward PE | 29.76 | 29.84 | 17.38 | 23.53 | 23.90 | 37.04 |
P/FCF Ratio | - | - | - | - | - | 77.51 |
PS Ratio | 1.53 | 1.69 | 1.62 | 2.20 | 3.14 | 7.94 |